Fig. 4: Global germline loss of either Gipr or Glp-1r blocks GIPR antagonism-mediated effects on body weight and food intake.
a–c, Body weight in grams (a) and percent (b) and food intake (c) of HFD-fed 14–16-week-old male C57BL6/J WT mice treated s.c. with a single dose (30 mg kg−1) of either a control mAb (vehicle; n = 5) or an anti-GIPR antagonist (ant.) antibody (n = 6). d–f, Body weight in grams (d) and percent (e) and food intake (f) of HFD-fed 14–16-week-old male C57BL6/J global Gipr KO mice treated s.c. with a single dose (30 mg kg−1) of either a control mAb (vehicle) or an anti-GIPR antagonist antibody (n = 6 each group). g–i, Body weight in grams (g) and percent (h) and food intake (i) of HFD-fed 14–16-week-old male C57BL6/J global Glp-1r KO mice treated s.c. with a single dose (30 mg kg−1) of either a control mAb (vehicle) or an anti-GIPR antibody (n = 6 each group). Data represent mean ± s.e.m. *P < 0.05, **P < 0.01 and ***P < 0.001. Data in a–i were analysed by a two-way ANOVA with Bonferroni’s post hoc test for comparison of individual timepoints.
